Gene therapy could ease rare hormone disorder

NCT ID NCT04783181

First seen Jan 06, 2026 · Last updated May 13, 2026 · Updated 13 times

Summary

This study tests a new gene therapy for adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production. The treatment delivers a working copy of the CYP21A2 gene using a harmless virus. Researchers aim to see if it is safe and can reduce abnormal hormone levels, potentially allowing patients to lower their daily steroid medications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Ann and Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Lucas Research, Inc.

    Morehead City, North Carolina, 28557, United States

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892-1932, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

Conditions

Explore the condition pages connected to this study.